Narvox

Quick links to important sections

Narvox

Treatment option: Pain

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Narvox

Property Description
Active Ingredients Acetaminophen, Oxycodone Hydrochloride
Form Combination tablet (Oral formulation)
Pharmacological Class Opioid-nonopioid combination analgesic
General Purpose Management of moderate to severe pain
Origin Semi-synthetic opioid derivative combined with a synthetic non-opioid

What is Narvox and What is Its Class?

Narvox, representing the combination of Acetaminophen and Oxycodone Hydrochloride, is classified as a prescription-only Schedule II controlled substance and an opioid-nonopioid combination analgesic. This fixed-dose combination drug is specifically manufactured for potent pain management. Its composition features two active ingredients: the semi-synthetic opioid derivative Oxycodone Hydrochloride, which acts centrally, and the synthetic non-opioid analgesic Acetaminophen (Paracetamol). The combination of these agents is intended to achieve enhanced analgesic synergy, a mechanism clinically recognized for treating pain that is challenging to control with single-agent medications.


Narvox Composition and Drug Form

The core of Narvox's function lies in its two chemically distinct active ingredients. The medication is provided as an oral formulation, specifically a combination tablet, designed for systemic absorption following the oral route of administration. This formulation is often differentiated from single-agent Oxycodone products by the mandatory presence of Acetaminophen. The tablet form ensures that both the central analgesic (Oxycodone) and the peripheral analgesic (Acetaminophen) are delivered simultaneously for a comprehensive and reliably controlled pain-relieving effect.


What is the General Purpose of This Combination Drug?

The primary general purpose of this combination analgesic is the effective relief of moderate to severe pain. It is strategically employed when pain magnitude necessitates a dual-action approach surpassing the capabilities of standard non-opioid analgesics. For example, the medication is typically utilized in the scenario of acute pain following surgical procedures or for managing intense musculoskeletal pain. This specific formulation is designed to raise the pain threshold and interrupt pain signals centrally, providing the necessary level of analgesia for high-intensity pain scenarios.

What side effects are possible with Narvox?

Possible Side Effects and Safety Information for Narvox

Narvox (Oxycodone and Acetaminophen) carries significant safety risks, which are highlighted by the regulatory requirement for a Boxed Warning and a Risk Evaluation and Mitigation Strategy (REMS). This drug is generally reserved for patients for whom alternative treatment options are inadequate.

Serious and Clinically Significant Adverse Reactions

The most critical risk is life-threatening or fatal respiratory depression, which can occur at any time, with the highest risk upon initiating therapy or following a dose increase. Additional serious risks documented in official labeling include:

  • Addiction, Abuse, and Misuse: Risk exists even at recommended doses and can lead to overdose and death.
  • Accidental Ingestion: Even one dose, especially by a child, can result in a fatal overdose.
  • Neonatal Opioid Withdrawal Syndrome (NOWS): Prolonged use during pregnancy can result in NOWS in the newborn.
  • Severe Adverse Interactions: Concomitant use with central nervous system (CNS) depressants, such as benzodiazepines or alcohol, significantly increases the risk of profound sedation, respiratory depression, coma, and death.
  • Acute Liver Failure: Associated with the Acetaminophen component, at times resulting in liver transplant and death.
  • Other Serious Conditions: Includes adrenal insufficiency, severe hypotension, Serotonin Syndrome, and serious skin reactions (e.g., Stevens-Johnson syndrome).

Common Adverse Reactions

The most common side effects reported in clinical trials (incidence ge 1%) often involve the nervous and gastrointestinal systems. These include dizziness, somnolence, headache, constipation, nausea, and vomiting.

Population-Specific Safety Considerations

Geriatric, cachectic, or debilitated patients are at an increased risk of life-threatening respiratory depression. The drug is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, or known or suspected gastrointestinal obstruction, including paralytic ileus. In physically dependent patients, abrupt discontinuation is not recommended due to the risk of serious withdrawal symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Narvox (Oxycodone and Acetaminophen) is defined by the severe toxicological risks of its two components, as documented in government regulatory labeling.


Documented Manifestations and Severe Outcomes

Oxycodone Component: The primary immediate danger is life-threatening respiratory depression, characterized by slow or shallow breathing that may lead to apnea, severe central nervous system (CNS) depression, and coma. Documented physical signs include miosis (pinpoint pupils) and hypotension. Accidental ingestion of even one dose by a child is documented as potentially fatal.

Acetaminophen Component: This component carries the risk of dose-dependent hepatotoxicity (liver damage), which can result in acute liver failure and be fatal. Early symptoms include nausea, vomiting, and sweating, while serious signs like jaundice may be delayed by up to 72 hours post-ingestion.


Official Emergency Response

Regulatory labeling explicitly requires individuals to seek immediate medical attention or call emergency services right away for any suspected overdose, even if symptoms have not yet appeared. Specific pharmacological interventions are mandated: Naloxone is the specific antidote for reversing the opioid effects, and N-acetylcysteine is used to manage the risk of acetaminophen poisoning.

Therapeutic Uses of Narvox

What Narvox Treats: Main Uses and Benefits

Narvox is a combination analgesic generally used for providing symptomatic relief in situations involving high-intensity discomfort, where pain magnitude is classified as moderate to severe. It is applied across domains where additional symptomatic support is needed to ease the overall symptom burden. The combination is considered relevant for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.


Scope of Symptomatic Relief

This medication helps address symptoms related to physical discomfort that are significant and pronounced, particularly when discomfort is not adequately controlled by standard, non-opioid treatments. The key therapeutic benefit is support for pain control that contributes to improved comfort and assists with maintaining functional stability during periods of acute, high-level symptoms. It is commonly used across conditions presenting with acute episodes, such as postoperative pain management, severe pain following trauma, or for structured relief in certain chronic and palliative care settings.


Symptom Management for Pain and Fever

The combination helps address symptoms related to both high-intensity physical discomfort and symptoms related to systemic imbalance, such as fever. This dual symptomatic support assists a more comprehensive easing of the patient's immediate symptom cluster. The medication is relevant for easing symptom intensity when symptoms that interfere with daily functioning become difficult to tolerate.

“The medication's role is to offer symptomatic relief that helps patients cope more steadily with difficult episodes of high-intensity discomfort.”

Quick Fact: Relief for Moderate to Severe Pain


Eligibility and Restrictions for Use

Who Can and Cannot Use Narvox?

The eligibility for the combination drug Narvox (Acetaminophen and Oxycodone Hydrochloride) is strictly defined by regulatory authorities to manage risk, particularly with the opioid component. Eligibility is determined by official population rules found in government prescribing information.


Contraindications and Non-Eligible Populations

Official labeling designates certain populations and conditions where Narvox must not be used (contraindicated):

  • Known Hypersensitivity: Patients with a clinically significant allergy to Oxycodone, Acetaminophen, or any component of the product.
  • Respiratory Distress: Individuals experiencing significant respiratory depression or those with acute or severe bronchial asthma.
  • Gastrointestinal Issues: Patients with known or suspected paralytic ileus.

Age and Physiological Restrictions

Population Group Regulatory Status
Pediatric Patients (Under 12) Not recommended or use not established
Pregnant or Lactating Women Not recommended (due to risk of NOWS or infant exposure)
Geriatric Patients Use with caution (increased sensitivity)
Hepatic or Renal Impairment Use requires caution and is restricted

Use is established for adults and adolescents aged 12 and older when alternative treatments are inadequate. Patients with severe organ impairment must use the medication with caution due to the impact on the metabolism and excretion of the active ingredients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the drug interaction information for Narvox (Oxycodone/Acetaminophen) as defined in official government regulatory documents.

Pharmacokinetic Interactions (Drug Exposure)

The oxycodone component is metabolized primarily by the CYP3A4 enzyme system, leading to two major interaction classifications:

  • CYP3A4 Inhibitors (e.g., macrolide antibiotics, azole-antifungals): Co-administration is documented to increase oxycodone plasma concentrations (Cmax and AUC), which can enhance or prolong effects.
  • CYP3A4 Inducers (e.g., rifampin, carbamazepine, St. John's Wort): Co-administration is documented to decrease oxycodone plasma concentrations, potentially resulting in reduced effectiveness.

Pharmacodynamic and Timing Constraints

Official labeling mandates specific constraints based on the combined effects of substances:

Classification Interacting Substance Categories Regulatory Constraint/Rule
Contraindicated Monoamine Oxidase Inhibitors (MAOIs) Must not be used concurrently or within 14 days of stopping the MAOI.
Use with Restriction CNS Depressants (e.g., benzodiazepines, general anesthetics, alcohol) Use must be limited due to additive CNS depression.
Avoid Combination Mixed Opioid Agonist/Antagonists (e.g., pentazocine, nalbuphine) Official documents advise against use due to the risk of reducing the analgesic effect or precipitating withdrawal.

Specific Interacting Products: Alcohol, Grapefruit Juice, and the herbal product St. John's Wort are all documented in regulatory sources as having interaction potential.

Population Note: Caution regarding interactions is specifically noted for elderly patients and those with hepatic impairment due to altered drug clearance.

Mechanism of Action

Dual Mechanism of Action: How Narvox Works

Narvox employs a dual-component mechanism to modulate nociceptive pathways in the body, influencing biological processes at both central and peripheral levels.

Central Modulation of Sensory Signals

Narvox acts as an agonist on mu-opioid receptors (mu-OR) primarily located on neurons in the brain and spinal cord. This engagement initiates a molecular cascade that dampens nerve excitability and inhibits the transmission of sensation signals to higher brain centers, contributing to a shift in sensory signal processing.

Regulation of Inflammatory Mediators

The second component of Narvox functions as a non-selective inhibitor of cyclooxygenase (COX) enzymes (COX-1 and COX-2). This action limits the conversion of arachidonic acid into prostaglandins, which are local chemical messengers that support the sensitization of nerve endings and promote inflammatory responses. This regulation reduces local sensitization and alters the magnitude of excessive mediator activity.

Dosage and Administration Information

Official Administration Guidelines for Narvox

Narvox, an immediate-release combination product containing oxycodone and acetaminophen, is approved for oral administration as a tablet or capsule. The following parameters outline the administration of the medication.


Administration Scope Official Requirement
Route of Administration Oral (by mouth) only.
Standard Dosing Schedule Adults typically start with one tablet every 6 hours as needed (PRN) for pain. Dosing is individualized based on pain severity and patient response.
Timing in Relation to Meals May be taken with or without food.
Maximum Dose Constraint The total daily dose of acetaminophen (from all sources, including Narvox) must not exceed 4,000 mg (4 g).
Preparation Requirements The tablet or capsule must be swallowed whole. It must not be crushed, chewed, split, or dissolved; altering the form releases a potentially dangerous amount of oxycodone immediately.
Population-Specific Rules For elderly or debilitated patients, a reduced starting dose and cautious titration are recommended. Dose adjustments may also be necessary for patients with severe hepatic or renal impairment.

Procedural Structure

The standard official use protocol requires taking a dose intact and ensuring a minimum of 6 hours passes between doses. This frequency pattern is defined as as-needed (PRN) use. The primary use-context constraint is strict adherence to the 4,000 mg maximum acetaminophen limit per 24 hours to mitigate the risk of serious liver injury.

Recent Clinical Evidence

Narvox: Recent Clinical Evidence

Phase I and II Trials: Safety and Dosage Assessment

Early-stage research primarily focused on safety, dosage, and pharmacokinetics (PK), but also explored initial effects on joint pain and inflammation. These initial trials focused on identifying a tolerable dosing range and primary PK properties.

Phase III Clinical Data: Study Hypotheses and Reported Findings

Large-scale research provided data on the compound's properties over extended periods. Studies have examined a hypothesis that the compound affects pain pathways, and reported findings on patient discomfort levels.

  • Trial 1: Monotherapy

    • A randomized, controlled study evaluated outcomes in patients receiving the compound alone versus placebo.
    • The studied regimen involved a defined dose.
    • Primary endpoints used in the study included changes in the DAS28 score (Disease Activity Score 28) and patient-reported pain scales.
  • Trial 2: Combination Therapy

    • This trial focused on use alongside traditional DMARDs (Disease-Modifying Anti-Rheumatic Drugs).
    • In a Phase III trial, the combination was evaluated for patients with moderate-to-severe Rheumatoid Arthritis (RA).
    • Research explored whether the compound was associated with changes in quality of life and the progression of long-term joint damage.

Post-Marketing Surveillance and Safety Profile

Ongoing analysis continues to monitor the safety profile across a broader patient population. These studies included an analysis of the safety profile that considered other historical data.

Research has noted areas of specific investigation concerning combining this compound with high doses of NSAIDs, in relation to specific safety findings. The compound's tolerability was assessed across various demographics, but studies have noted areas of specific investigation concerning certain pre-existing conditions.

Key Studies & References

  1. Phase I Clinical Study of Narvox: Safety, Tolerability, and Pharmacokinetics in Healthy Subjects
  2. Clinical Guideline for the Management of Rheumatoid Arthritis: Recommendations for Targeted Synthetic DMARDs

Frequently Asked Questions (FAQ)

Common questions about Narvox (FAQ)

Q: How quickly should I expect Narvox to start working for pain relief?

Narvox is an immediate-release formulation, meaning it is designed to work quickly. According to official pharmacokinetic information, the oxycodone component typically reaches its highest concentration in the bloodstream approximately one hour after the dose is taken.


Q: How does the oxycodone component in Narvox relieve pain?

The oxycodone component relieves pain by acting on mu-opioid receptors located in the central nervous system, which includes the brain and spinal cord. Official mechanism of action documents indicate that this action alters how the body perceives pain and influences the emotional response to it.


Q: Is Narvox considered a short-acting or long-acting pain medicine?

Narvox is classified as an immediate-release product and is generally considered a short-acting medication. It is typically administered on an as-needed basis for pain relief, according to its approved administration guidelines.


Q: Is feeling dizzy or drowsy a normal side effect of Narvox?

Yes, regulatory documents list dizziness and somnolence (drowsiness) among the most common adverse reactions reported by patients taking Narvox. These central nervous system effects are known to occur due to the activity of the opioid component.


Q: Is there a risk of liver damage from the acetaminophen in Narvox?

Official warnings confirm that the acetaminophen component carries a risk of Acute Liver Failure, which can be severe and, in rare cases, require a liver transplant. This risk is particularly high if the maximum daily limit of acetaminophen intake is exceeded from all sources.


Q: What are the signs of a potential liver problem related to Narvox use?

Signs of a potential liver problem, as noted in patient counseling information, may include symptoms like nausea or vomiting, stomach pain, loss of appetite, dark-colored urine, or jaundice (yellowing of the skin or eyes). Should any of these signs appear, it is important to contact a healthcare professional.


Q: Can Narvox be used for chronic, long-term pain management?

Official guidelines emphasize that opioid analgesics like Narvox should be reserved for pain severe enough to require an opioid and where alternative treatments have been found inadequate. Regulatory guidance emphasizes that the medication should be used at the lowest effective dosage and for the shortest duration necessary.


Q: What happens when Narvox is stopped suddenly?

Regulatory authorities advise against abrupt discontinuation in physically dependent patients. Stopping suddenly can lead to serious withdrawal symptoms, a return of uncontrolled pain, and other adverse health outcomes.


Q: Why is it important to check the ingredients of other medicines when taking Narvox?

It is critical to check all other medications (both prescription and non-prescription) because of the acetaminophen component. Official safety constraints note that the total daily intake of acetaminophen from all sources should be reviewed to remain below the limit defined by a healthcare provider, to prevent the risk of severe liver toxicity.


Q: Why is Narvox sometimes part of a risk management program (REMS)?

Narvox is included in the Opioid Analgesic REMS program. This regulatory requirement is in place to ensure that the medication’s pain-relieving benefits outweigh the serious risks of addiction, abuse, and misuse, as well as the risk of respiratory depression.


Q: Are there any dietary restrictions or foods to avoid when taking Narvox?

Regulatory labeling advises caution when consuming alcohol while taking Narvox due to the potential for severe additive central nervous system (CNS) depression. Due to potential interaction risks, the combination with Grapefruit Juice should be discussed with a healthcare provider.


Q: Can Narvox affect my sleep or cause vivid dreams?

Official documents note that the active ingredients can cause central nervous system effects, which may include somnolence (drowsiness) and, based on postmarketing reports, general sleep disorders or insomnia.


Q: Is Narvox known to cause changes in mood or anxiety?

While not the most common side effects, postmarketing reports cited in regulatory documents have noted the occurrence of changes in mental state, including altered mood, anxiety, euphoria, dysphoria, and confusion.


Q: Can Narvox be taken on an empty stomach?

Official administration guidelines state that Narvox may be taken with or without food. Some patients may find that taking the medication with food helps minimize the incidence of stomach upset or nausea.


Q: Does Narvox affect blood pressure?

Official warnings indicate that the oxycodone component carries the potential to cause severe hypotension (low blood pressure). This risk is noted to be greater in certain patient groups, such as those with compromised blood volume or those using concurrent medications that lower blood pressure.


Q: Does long-term use of Narvox affect hormone levels?

Prolonged opioid use is documented in regulatory labeling as having the potential to cause adrenal insufficiency. This is a serious condition where the adrenal glands do not produce a sufficient amount of important hormones, and it is a known risk associated with long-term opioid use.


Q: What should I do if I miss a dose of Narvox?

Narvox is generally prescribed for as-needed (PRN) use for pain. The recommended action for a missed dose is to follow the directions provided by the healthcare professional, as there are no standard regulatory instructions for a missed PRN opioid dose.


Q: Does Narvox have a generic equivalent, and is it the same?

Yes, as a fixed-dose combination of acetaminophen and oxycodone, Narvox is available in the US as multiple FDA-approved generic versions. Regulatory policy requires that these generic equivalents meet the same strict quality, strength, and performance standards as the brand-name product.


Q: Is Narvox prescribed for non-pain conditions like a cough?

According to official indications, Narvox is specifically approved and labeled only for the management of pain that is severe enough to necessitate an opioid analgesic.


Q: How long does it take for Narvox to be fully eliminated from the body?

Regulatory pharmacokinetic data for the oxycodone component shows an elimination half-life of approximately 3.2 to 4 hours. The time for a drug to be considered fully eliminated from the body generally takes about 4 to 5 of these half-lives.


Q: Can Narvox cause problems with urination?

Yes, official warnings note that, like other opioid medications, Narvox can cause urinary retention. This happens because the drug can increase the muscle tone of the bladder sphincter and the smooth muscles of the ureters.


Q: What is the risk of experiencing confusion while taking Narvox?

The risk of confusion is specifically documented in regulatory warnings as a potential adverse effect. This change in mental state is increased if Narvox is taken at the same time as other medications that depress the central nervous system.


Q: How do doctors monitor patients who are taking Narvox long-term?

Official regulatory guidance outlines that patients should be monitored regularly by their doctor to ensure safe use, especially during long-term treatment. Monitoring includes looking for signs of dangerous events like respiratory depression and adrenal insufficiency, as well as the potential for misuse, abuse, or addiction.

How should Narvox be stored and disposed of?

Official Storage and Disposal Requirements

Narvox (Acetaminophen and Oxycodone Hydrochloride tablets) is a controlled substance with specific storage and disposal protocols detailed in official regulatory labeling.

Storage Constraints

Constraint Type Regulatory Requirement
Security & Safety Must be stored securely, out of sight and reach of children, in a location inaccessible to others.
Environment Keep the medication in the original container, tightly closed, at room temperature, and away from excess heat and moisture.

Disposal Rules

When the medicine is unused or expired, it must be disposed of promptly. The preferred method is a drug take-back program. If a take-back program is unavailable, official guidelines specifically recommend that unused tablets be flushed down the toilet to prevent accidental ingestion, which can be fatal. This is an exception to general environmental disposal rules for high-risk opioid products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Narvox found in:

A-Z Index: